drugset / Trial / NCT06977880
A Phase 1, First-in-human Study of MORF-440 (LY4292009) in Healthy Participants
RandomizedParallel-groupSingle-blindBasic science
Summary
The purpose of this study is to evaluate the safety and tolerability of single ascending doses of MORF-440 administered to healthy participants single-ascending dose (SAD) and maximum ascending dose (MAD) substudy.
Timeline
- Start
- 2025-02-19
- Primary completion
- 2026-03-20
- Completion
- 2026-03-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY4292009 | Unknown | — | Oral |
Indications
No indication recorded.